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Lack of Evidence of a
Clopidogrel–Statin Interaction in the CHARISMA Trial
Jacqueline Saw, MD,* Danielle M. Brennan, MS,† Steven R. Steinhubl, MD,‡
Deepak L. Bhatt, MD,† Koon-Hou Mak, MD,§ Keith Fox, MB, CHB, Eric J. Topol, MD,#
on behalf of the CHARISMA Investigators
Vancouver, British Columbia, Canada; Cleveland, Ohio; Lexington, Kentucky; Singapore;
Edinburgh, Scotland, United Kingdom; and La Jolla, California
Objectives The purpose of this study was to evaluate the potential impact of clopidogrel and statin interaction in a random-
ized, placebo-controlled trial with long-term follow-up.
Background There are conflicting data regarding whether statins predominantly metabolized by CYP3A4 reduce the metabo-
lism of clopidogrel to its active metabolite and diminish its clinical efficacy.
Methods The CHARISMA trial was a randomized trial comparing long-term 75 mg/day clopidogrel versus placebo in pa-
tients with cardiovascular disease or multiple risk factors on aspirin. The primary end point was a composite of
myocardial infarction, stroke, or cardiovascular death at median follow-up of 28 months. We performed a sec-
ondary analysis evaluating the interaction of clopidogrel versus placebo with statin administration, categorizing
baseline statin use to those predominantly CYP3A4 metabolized (atorvastatin, lovastatin, simvastatin; CYP3A4-
MET) or others (pravastatin, fluvastatin; non–CYP3A4-MET).
Results Of 15,603 patients enrolled, 10,078 received a statin at baseline (8,245 CYP3A4-MET, 1,748 non–CYP3A4-MET)
and 5,496 did not. For the overall population, the primary end point was 6.8% with clopidogrel and 7.3% with
placebo (hazard ratio [HR] 0.93; p  0.22). This was similar among patients on CYP3A4-MET (5.9% clopidogrel,
6.6% placebo, HR 0.89; p  0.18) or non–CYP3A4-MET statin (5.7% clopidogrel, 7.2% placebo, HR 0.78; p 
0.19). There was no interaction between statin types and randomized treatment (p  0.69). Patients on ator-
vastatin (n  4,127) (5.7% clopidogrel, 7.1% placebo, HR 0.80; p  0.06) or pravastatin (n  1,440) (5.1%
clopidogrel, 7.0% placebo, HR 0.72; p  0.13) had similar event rates.
Conclusions Despite theoretic concerns and ex vivo testing suggesting a potential negative interaction with concomitant clo-
pidogrel and CYP3A4-MET statin administration, there was no evidence of an interaction clinically in a large
placebo-controlled trial with long-term follow-up. (J Am Coll Cardiol 2007;50:291–5) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.097(
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Clopidogrel and 3-hydroxy-3-methyglutaryl
coenzyme A reductase inhibitors (statins) are
frequently coadministered in patients with
atherosclerosis, especially those who have
undergone stent implantation. Furthermore,
clopidogrel and several statins are predomi-
antly metabolized by cytochrome P450 3A4 isoenzyme
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enter, Singapore; University and Royal Infirmary of Edinburgh, Edinburgh,
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Manuscript received November 7, 2006; revised manuscript received January 19,
007, accepted January 22, 2007.CYP3A4) in vivo for activation and elimination, respec-
ively (1,2). Thus, any drug–drug interactions that may
dversely affect the efficacy of either drug could radically
See page 296
lter our standard treatment armamentarium. Such an inter-
ction between clopidogrel and atorvastatin was first described
n an ex vivo experiment using the point-of-care Plateletworks
est by Lau et al. in 2003 (3). Since then, several other ex vivo
tudies using light transmission aggregometry and flow cytom-
try have yielded conflicting results (1,4–11). In addition, we
nd others have studied the clinical impact of such a potential
nteraction between clopidogrel and CYP3A4-metabolized
tatins and have found no adverse interaction (12–14). The major
riticisms of those clinical studies were their small sample
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though a large randomized study
comparing CYP3A4-metabolized
versus non–CYP3A4-metabolized
statins in patients on clopidogrel
(with evaluation of platelet aggre-
gation, activation, and clinical end
points) would be ideal to solve this
controversy, such a study would
require tremendous resources and
laboratory personnel support and,
herefore, is not likely to be executed.
The CHARISMA (Clopidogrel for High Atherothrom-
otic Risk and Ischemic Stabilization, Management, and
voidance) study (15) inclusive of 15,603 high-risk patients
rovided an opportunity to more definitively evaluate the
linical impact of concomitant clopidogrel and statin ther-
py. We therefore performed a secondary analysis of
HARISMA, stratifying patients into statins administered
ccording to CYP3A4 metabolism.
ethods
he design, methods, and primary results of the CHARISMA
tudy have been described in detail previously (15). To
ummarize, CHARISMA was a prospective, multicenter,
ouble-blind, randomized, placebo-controlled trial compar-
ng long-term 75 mg/day clopidogrel versus placebo in
atients at high risk for cardiovascular events. All patients
lso received low-dose (75 to 162 mg/day) aspirin. Inclusion
riteria were patients age 45 years with either multiple
therothrombotic risk factors or documented coronary dis-
ase, cerebrovascular disease, or symptomatic peripheral
rterial disease. Patients were excluded if they were judged
o have established indications for clopidogrel therapy (e.g.,
cute coronary syndrome, stent implantation). The follow-up
as at 1 month, 3 months, 6 months, and every 6 months
hereafter until the end of the trial. The primary efficacy end
oint was the first occurrence of myocardial infarction (MI),
troke, or cardiovascular death with the median of 28
onths follow-up. The primary safety end point was major
leeding according to the GUSTO (Global Utilization of
treptokinase and Tissue Plasminogen Activator for Oc-
luded Arteries) definition (16), which includes fatal bleed-
ng and intracranial hemorrhage or bleeding that caused
emodynamic compromise requiring blood or fluid replace-
ent, inotropic support, or surgical intervention.
We performed a secondary analysis of the CHARISMA
rial, evaluating the differential treatment effect (interaction)
f clopidogrel versus placebo according to the type of statin
dministration. Statin administration was nonrandomized
nd directed by the treating physicians. We divided patients
nto 2 major groups according to baseline statin adminis-
ration: 1) those receiving statins that are predominantly
etabolized by CYP3A4 (atorvastatin, lovastatin, simvasta-
Abbreviations
and Acronyms
CI  confidence interval
CYP3A4-MET 
cytochrome P450 3A4-
metabolized statin
HR  hazard ratio
MI  myocardial infarction
OR  odds ratioin; CYP3A4-MET); and 2) those on statins that are not aredominantly metabolized by CYP3A4 (pravastatin, fluva-
tatin; non–CYP3A4-MET). Additionally, clinical out-
omes were evaluated separately in patients receiving ator-
astatin or pravastatin. We compared the relative efficacy of
lopidogrel versus placebo on the primary efficacy and safety
nd points according to the type of statin administered. The
nalyses were performed on the entire cohort of the
HARISMA trial patients as well as the subgroup of
atients with established cardiovascular disease.
tatistics. All data analyses were performed on the intention-
o-treat population. Hypothesis tests were done using 2-sided
ests at the 5% significance level. Baseline characteristics were
ompared with chi-square tests for discrete and continuous
ariables. The primary efficacy of clopidogrel versus placebo
as assessed with the log rank test. Statistical comparisons of
he primary safety end point in the 2 treatment groups were
erformed with Pearson chi-square test. The treatment effect,
easured by the hazard ratio (HR) and its 95% confidence
nterval (CI), was estimated with the Cox proportional hazards
odel for the primary efficacy end point and by odds ratios
OR) and 95% CI from logistic regression model for the
rimary safety end point. Interactions were tested in a Cox
roportional hazards model, incorporating terms for random-
zed treatment, statin, and the treatment-by-statin interaction,
o assess if treatment effect differed for CYP3A4-MET versus
on–CYP3A4-MET and atorvastatin versus pravastatin. All
tatistical analyses were performed with SAS software (version
.2; SAS Institute, Cary, North Carolina).
esults
atient characteristics. The CHARISMA trial enrolled
5,603 patients, with 7,802 randomized to clopidogrel and
,801 randomized to placebo. Of these, 10,078 (64.6%) were
n a statin before randomization: 8,245 were on a CYP3A4-
ET statin (4,127 on atorvastatin) and 1,748 were on a
on–CYP3A4-MET statin (1,440 on pravastatin). We ex-
luded 29 patients who were listed as being on both types of
tatins. The baseline demographics are described in Table 1.
atients in the CYP3A4-MET group were slightly younger,
ad a greater body mass index, and had a higher prevalence of
ypercholesterolemia, peripheral arterial disease, prior strokes,
arotid endarterectomy, and coronary artery bypass surgery.
he median follow-up was 28 months.
rimary efficacy end point (MI, stroke, or cardiovascular
eath). In the overall study population, the primary end
oint was 6.8% with clopidogrel and 7.3% with placebo
HR 0.93, 95% CI 0.83 to 1.05; p 0.23). This was similar
ith the use of statins (clopidogrel 5.9%, placebo 6.7%, HR
.87, 95% CI 0.75 to 1.02; p  0.084), irrespective of the
ype used (Fig. 1): CYP3A4-MET (5.9% clopidogrel, 6.6%
lacebo, HR 0.89, 95% CI 0.75 to 1.06; p  0.18) or
on–CYP3A4-MET (5.7% clopidogrel, 7.2% placebo, HR
.78, 95% CI 0.54 to 1.13; p 0.19). The interaction of the
ype of statin (CYP3A4-MET vs. non–CYP3A4-MET)
nd randomized treatment was not significant (p  0.69).
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July 24, 2007:291–5 Lack of Clopidogrel–Statin Interactionmong patients not on a statin, the primary end point was
.7% with clopidogrel versus 8.5% with placebo (HR 1.02,
5% CI 0.85 to 1.22; p  0.87).
torvastatin versus pravastatin. The long-term primary
nd point was also similar irrespective of atorvastatin or
ravastatin administration with clopidogrel. Among pa-
ients who received atorvastatin, the primary end point was
.7% with clopidogrel, 7.1% with placebo (HR 0.80, 95%
I 0.62 to 1.01; p  0.06). Among patients on pravastatin,
he primary end point was 5.1% with clopidogrel, 7.0% with
lacebo (HR 0.72, 95% CI 0.47 to 1.10; p  0.13). The
aseline Characteristics of Patients
Table 1 Baseline Characteristics of Patients
Characteristics
All Patients
(n  1,5574)
No Statins
(n  5,496)
Age, mean (SD), yrs 64.3 (9.6) 64.9 (9.9)
Female, n (%) 4,633 (29.7) 1,850 (33.7)
Weight, mean (SD), kg 81.8 (17.4) 79.1 (17.3)
BMI, mean (SD), kg/m2 28.6 (5.2) 28.1 (5.3)
Clinical history, n (%)
Active smoking 1,795 (11.5) 745 (13.6)
Diabetes 6,542 (42.0) 2,379 (43.3)
Hypertension 11,458 (73.6) 4,045 (73.6)
Hypercholesterolemia 11,506 (73.9) 2,398 (43.6)
Previous MI 5,384 (34.6) 988 (18.0)
Previous CHF 924 (5.9) 264 (4.8)
Previous stroke 3,828 (24.6) 1,891 (34.4)
Previous TIA 1,859 (11.9) 831 (15.1)
Peripheral arterial disease 3,523 (22.6) 1,330 (24.2)
Previous PCI 3,545 (22.8) 525 (9.6)
Previous CABG 3,073 (19.7) 506 (9.2)
Previous CEA 824 (5.3) 211 (3.8)
CYP3A4-MET versus non–CYP3A4-MET.
BMI  body mass index; CABG  coronary artery bypass surgery; CEA  carotid endarterectomy
IA  transient ischemic attack.
Figure 1 CV Death, MI, and Stroke
Primary end point of cardiovascular (CV) death, myocardial infarction (MI), or strok
randomized to clopidogrel or placebo, according to statin administration. CYP3A4-Mnteraction of atorvastatin versus pravastatin and random-
zed treatment was not significant (p  0.54).
leeding complications. There was no difference in the
rimary safety end point of major bleeding between the
roups: all patients (clopidogrel 1.6%, placebo 1.3%, OR
.24; p  0.11), no statin (clopidogrel 2.1%, placebo 1.7%,
R 1.29; p  0.20), any statin (clopidogrel 1.4%, placebo
.2%, OR 1.19; p  0.33), CYP3A4-MET (clopidogrel
.4%, placebo 1.2%, OR 1.19; p  0.39), non–CYP3A4-
ET (clopidogrel 1.3%, placebo 1.2%, OR 1.14; p 0.76),
torvastatin (clopidogrel 1.2%, placebo 1.3%, OR 0.87; p 
CHARISMA Patients
CYP3A4-MET Statin
(n  8,245)
Non–CYP3A4-MET Statin
(n  1,748) p Value*
63.9 (9.4) 64.4 (9.4) 0.048
2,278 (27.6) 478 (27.3) 0.810
83.7 (17.3) 81.5 (16.8) 0.001
29.0 (5.2) 28.5 (5.1) 0.001
871 (10.6) 171 (9.8) 0.332
3,418 (41.5) 702 (40.2) 0.318
6,098 (74.0) 1,254 (71.7) 0.056
7,488 (90.8) 1,544 (88.3) 0.001
3,615 (43.8) 754 (43.1) 0.584
553 (6.7) 99 (5.7) 0.109
1,545 (18.7) 376 (21.5) 0.008
830 (10.1) 184 (10.5) 0.563
1,844 (22.4) 330 (18.9) 0.001
2,490 (30.2) 517 (29.6) 0.604
2,173 (26.4) 373 (21.3) 0.001
521 (6.3) 86 (4.9) 0.026
congestive heart failure; MI myocardial infarction; PCI  percutaneous coronary intervention;
median of 28 months among patients
cytochrome P450 3A4-metabolized statin; HR  hazard ratio.e at a
ET 
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Lack of Clopidogrel–Statin Interaction July 24, 2007:291–5.61), and pravastatin (clopidogrel 1.3%, placebo 1.3%, OR
.04; p  0.93).
atients with established cardiovascular disease. There
ere 12,153 patients with established cardiovascular disease in
he overall CHARISMA study. In this symptomatic subgroup,
here was a marginally significant reduction in the primary end
oint with clopidogrel (6.9%) versus placebo (7.9%; HR 0.88,
5% CI 0.77 to 0.998; p 0.046). Given that this prespecified
ohort of patients had differential effects with clopidogrel from
he asymptomatic CHARISMA population (p  0.045 for
nteraction in the main CHARISMA manuscript), separate
nteraction analyses were performed. In the symptomatic sub-
roup, the interaction of the type of statin used (CYP3A4-
ET or non–CYP3A4-MET) and the randomized treat-
ent (clopidogrel vs. placebo) remained insignificant (p 
.18). Likewise, the interaction of atorvastatin versus prav-
statin and randomized treatment was not significant (p 
.25).
tatins versus no statins. The use of any statins at ran-
omization was associated with a lower primary end point
or both patients randomized to clopidogrel (5.9% statins,
.7% no statins; p  0.001) and to placebo (6.7% statins,
.5% no statins; p  0.001). However, there was no
ignificant interaction between the use of statins (vs. no
tatins) and randomized treatment (clopidogrel vs. placebo;
 0.21).
iscussion
he CHARISMA trial was a large randomized prospective
rial comparing long-term clopidogrel therapy with placebo
n patients deemed at high risk for atherothrombotic events
eceiving concomitant aspirin. The design of the study
llowed us to evaluate if there were any clinically relevant
nteractions with long-term concomitant clopidogrel and
tatin therapy. The present study is not only the largest
o-date, but it is also the only one that studied the clinical
mpact of long-term (1 year) coadministration of
lopidogrel and statins. We stratified the CHARISMA
atients according to the statin administered: no statin, any
tatin, CYP3A4-MET, non–CYP3A4-MET, atorvastatin,
r pravastatin. We found no difference in the relative
fficacy of clopidogrel compared with placebo at 28 months,
rrespective of the type of statin administered (CYP3A4-
ET or non–CYP3A4-MET, atorvastatin or pravastatin).
herefore, there is no clinically apparent adverse interaction
etween long-term administration of clopidogrel and statins
hat are predominantly CYP3A4 metabolized (i.e., atorva-
tatin, simvastatin, lovastatin).
Clopidogrel is an inactive prodrug that is metabolized to
ts active form in the liver by the cytochrome P450 enzyme,
rimarily by the CYP3A4 isoenzyme. Other isoenzymes
nvolved to lesser degrees include CYP3A5, CYP2B6, and
YP1A2 (1). Several statins are also metabolized in the
iver by CYP3A4 for elimination. Although 2 ex vivo
tudies showed that atorvastatin inhibited clopidogrel’s an- ciplatelet activity (3,5), both of those studies did not use the
old-standard light transmission aggregometry. In the study
y Lau et al. (3), platelet aggregation was assessed by the
edside Plateletworks test, which indirectly measures plate-
et aggregation using a cell counter to measure objects
xceeding the threshold platelet size. Likewise, Neubauer
t al. (5) used flow cytometry to evaluate ADP-stimulated
xpression of P-selectin as a marker of platelet activation,
ithout correlating to light transmission aggregometry.
In fact, all ex vivo studies using light transmission
ggregometry have contradicted the clopidogrel and statin
nteraction (4,6–11). For instance, in the INTERACTION
Interaction of Atorvastatin and Clopidogrel) study, Sere-
ruany et al. (8) prospectively assessed platelet function in
5 patients undergoing coronary stenting (pretreated with
25 mg/day aspirin and 300 mg loading clopidogrel) who
ad been taking atorvastatin, other statins, or no statins for
t least 30 days. They found similar platelet inhibition at 4 h
nd at 24 h, assessed by light transmission aggregometry
nd flow cytometry (e.g., PECAM-1, P-selectin, CD40
igand), irrespective of atorvastatin or other statin adminis-
ration. In the study by Mitsios et al. (7), patients with acute
oronary syndrome undergoing percutaneous coronary in-
ervention (n  30) were administered 375 mg loading
lopidogrel (followed by 75 mg/day) and randomized to 10
g atorvastatin or 40 mg pravastatin. Neither statin ad-
ersely affected clopidogrel’s platelet inhibition when as-
essed with light transmission aggregometry and flow cy-
ometry expressions of P-selectin and CD40 ligand.
urthermore, in the largest relevant laboratory study to date
539 of 1,001 patients undergoing catheterization were on
tatins), Hochholzer et al. (10) found that the use of
YP3A4-MET statins did not adversely affect platelet
ggregation with clopidogrel as assessed by light transmis-
ion aggregometry and flow cytometry surface expressions of
-selectin and activated glycoprotein IIb/IIIa. Of note,
hese studies were performed during the acute loading phase
f clopidogrel administration, where steady state may not
ave been achieved in all patients, given the individual
ariability of response to clopidogrel. However, in the study
y Vinholt et al. (9), in which patients with stable ischemic
eart disease (n  66) had been on 75 mg/day clopidogrel
or at least 10 weeks, there also was no adverse laboratory
nteraction with statins (irrespective of CYP3A4 metabo-
ism) when assessed with light transmission aggregometry.
Whether this controversial laboratory interaction translates
o adverse clinical events had been previously evaluated in
everal studies. In a post hoc analysis of the CREDO (Clopi-
ogrel for the Reduction of Events During Observation) study
n 2,116), we showed no statistical interaction in the 28-day
r 1-year composite death, MI, and stroke event rates with
oadministration of clopidogrel and a CYP3A4-MET statin in
atients who underwent coronary stenting (12). Wienbergen et
l. (13) analyzed the MITRA-PLUS (Maximal Individual
herapy of Acute Myocardial Infarction Plus) registry of acuteoronary syndrome patients on clopidogrel (n  2,086),
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July 24, 2007:291–5 Lack of Clopidogrel–Statin Interactionegregating patients into those receiving atorvastatin versus
ther statins (including both CYP3A4-MET and non–
YP3A4-MET statins). They found no difference in mortal-
ty or stroke events between the 2 groups at a median follow-up
f 14 months. In a single-center experience, Mukherjee et al.
14) also evaluated acute coronary syndrome patients (n 
,691) on clopidogrel and found no difference in major adverse
ardiac events at 6 months when they stratified patients
ccording to the use of CYP3A4-MET statin. In contrast, in
he observational study of the Quebec universal insurance
atabase by Brophy et al. (17) of 2,927 patients who underwent
ercutaneous coronary interventions and received clopidogrel,
hose who were prescribed atorvastatin had worse 30-day
utcomes than control subjects. However, there was no dose-
ependent relationship with atorvastatin administration, and
atients who were prescribed atorvastatin were likely a higher-
isk cohort, thus introducing bias into the analysis (18).
The present study confirms the results of the 3 previous post
oc analyses showing lack of clinical interaction between
lopidogrel and statins, extending the findings out beyond 2
ears of concomitant therapy. The other major strength of
he present study is the large patient population of the
HARISMA study. Excluding the MITRA-PLUS registry
which did not stratify patients according to CYP3A4 metab-
lism), we now have 3 studies concluding that the treatment
enefit of clopidogrel is similar in patients on concomitant
YP3A4-MET statin or non–CYP3A4-MET statin. Fur-
hermore, the present study suggests that this high-risk patient
ohort benefited from statin administration, with lower clinical
vent-rates compared with those not on statins.
tudy limitations. The major limitations of the present
tudy include its retrospective post hoc design, which
recludes definitive conclusions. The choice of statin ad-
inistered was at the discretion of treating physicians, and
hus potential selection bias may exist. However, clopidogrel
llocation was randomized and blinded; therefore, any bias
ntroduced by statin choice should be well balanced between
lopidogrel and control groups. We did not perform labo-
atory assessments of platelet aggregation or activation, and
he dose of statins administered and compliance with statins
ere not known. Our analyses were based upon baseline
tatin use, which is subject to error if there were major
hanges in statin prescription. However, when we evaluated
tatin usage over the study time period, we found an overall
bsolute 6% increase in statin use that was spread evenly
etween the different types of statins. Furthermore, when
e reanalyzed the data including only patients on the same
tatin throughout the study, the results and conclusions
emained unchanged (data not shown).
onclusions
ur secondary analysis of a large randomized placebo-
ontrolled trial with long-term follow-up showed no adverse
linical interaction with coadministration of clopidogrel and
tatins, irrespective of CYP3A4 metabolism. The concor-ant results from this study and other clinical analyses
olidify the recommendation that clinicians need not choose
tatins on the basis of CYP3A4 metabolism when clopi-
ogrel coadministration is necessary.
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EFERENCES
1. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed
by human cytochrome P450 3A and is inhibited by atorvastatin. Drug
Metab Dispos 2003;31:53–9.
2. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic
cytochrome p450 3A4 metabolic activity to the phenomenon of
clopidogrel resistance. Circulation 2004;109:166–71.
3. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the
ability of clopidogrel to inhibit platelet aggregation: a new drug-drug
interaction. Circulation 2003;107:32–7.
4. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany
VL. Onset and extent of platelet inhibition by clopidogrel loading in patients
undergoing elective coronary stenting: the Plavix Reduction of New Throm-
bus Occurrence (PRONTO) trial. Am Heart J 2003;145:239–47.
5. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A.
Lipophilic statins interfere with the inhibitory effects of clopidogrel on
platelet function—a flow cytometry study. Eur Heart J 2003;24:1744–9.
6. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of
statins on platelet inhibition by a high loading dose of clopidogrel.
Circulation 2003;108:2195–7.
7. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA,
Tselepis AD. Atorvastatin does not affect the antiplatelet potency of
clopidogrel when it is administered concomitantly for 5 weeks in patients
with acute coronary syndromes. Circulation 2004;109:1335–8.
8. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction
between atorvastatin or other statins and clopidogrel: results from the
interaction study. Arch Intern Med 2004;164:2051–7.
9. Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of
clopidogrel is not attenuated by statin treatment in stable patients with
ischemic heart disease. Thromb Haemost 2005;94:438–43.
0. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of
platelet inhibition after a 600-mg loading dose of clopidogrel in a
large, unselected cohort of candidates for percutaneous coronary
intervention. Circulation 2005;111:2560–4.
1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel
loading dose during coronary stenting: effects on drug response and
interindividual variability. Eur Heart J 2004;25:1903–10.
2. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-
atorvastatin clinical interaction from secondary analysis of a randomized,
placebo-controlled clopidogrel trial. Circulation 2003;108:921–4.
3. Wienbergen H, Gitt A, Shiele R, et al. Comparison of clinical benefits of
clopidogrel therapy in patients with acute coronary syndromes taking
atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285–8.
4. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of
clopidogrel-CYP3A4 statin interaction in patients with acute coronary
syndrome. Heart 2005;91:23–6.
5. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events. N Engl
J Med 2006;354:1706–17.
6. GUSTO Investigators. An international randomized trial comparing
four thrombolytic strategies for acute myocardial infarction. N Engl
J Med 1993;329:673–82.
7. Brophy JM, Babapulle MN, Costa V, Rinfret S. A pharmacoepidemiol-
ogy study of the interaction between atorvastatin and clopidogrel after
percutaneous coronary intervention. Am Heart J 2006;152:263–9.
8. Steinhubl SR, Akers WS. Clopidogrel-statin interaction: a mountain
or a mole hill? Am Heart J 2006;152:200–3.
